Refine by
Chronic Wounds Articles & Analysis
42 news found
There is a recovery period after treatment, and patients need to pay attention to wound protection and good care. Growth factor drugs can be used to promote wound healing and speed up tissue repair. ...
” “With 36 million people worldwide currently suffering from chronic wounds, we urgently need novel solutions for hard-to-treat wounds,” said Valerio Maria Ferrari, Bioseutica Group Chairman and Co-Founder of Healiva®. ...
Applicable people for CO2 fractional laser skin resurfacing treatment The main applicable population of CO2 fractional laser skin resurfacing treatment is all superficial scars and the early stage after wound healing. In the early stage after wound healing, fractional laser therapy can be used to regulate the process of wound healing and improve ...
Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection and chronic wound relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA. ...
The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the pravibismane program with this latest patent providing protection through to 2039. ...
“Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. ...
The dermaPACE® System is currently licensed or approved for advanced wound care indications in Brazil, Mexico and dozens of countries around the world. ...
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own ...
(SNWV) focuses on the development and commercialization of innovative advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications of shockwave and ultrasound systems in the non-medical field, announced today the patent activity for the past year. ...
Nature, Sci Rep 8, 962 (2018). https://doi.org/10.1038/s41598-018-19268-3 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. ...
Décory occurs in parallel with the company successfully completing an exclusive license and collaboration agreement with XBiome, for the clinical development and commercialization of AUP-16, Aurealis investigational therapy for Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory diseases, in greater China. Laurent brings to the company ...
“In published clinical studies, the antimicrobial Microlyte Matrix has been shown to jump start healing of stalled chronic wounds, and also reduce the incidence of surgical-site infections in high-risk patients”, said Dr. ...
Advanced Oxygen Therapy Inc. (AOTI), the leader in noninvasive sustained wound healing solutions, announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of combined strategic experience: Chief Medical Officer – Dr. Matthew G. Garoufalis is Co-Chair of the Alliance of Wound Care Stakeholders and past President of both the American ...
—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. ...
We believe that this partnership will accelerate the development of AUP-16 as a potential new therapy for DFU and other chronic wound patients.” said Juha Yrj nheikki, Aurealis CEO. “At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide. DFUs and other chronic ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. ...
It can revolutionize, supplement and in some cases even replace conventional treatment methods in medical technology, e.g., in surgery to prevent infections in post-operative wounds. In nursing service, cold atmospheric plasma offers a therapeutic option to treat chronic and hard to heal wounds. ...
“An advanced version of our FDA-cleared Microlyte® Matrix wound dressing kills bacteria hidden in biofilms. The new matrix is ultrathin, bioresorbable, provides a template for cell growth, and can prevent biofilm infections in wounds for several days. This award will fund a prospective human clinical trial of the novel antibiofilm matrix on donor site ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. ...